DREAMM-8: Belantamab mafodotin plus Pd significantly increases sustained MRD negativity rates in patients with RRMM

ASH 2025

Multiple Myeloma (MM)

DREAMM-7: Belantamab mafodotin combination achieves superior MRD outcomes in patients with RRMM

Multiple Myeloma (MM)

Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial

Lancet Haematol

Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, Spicka I, Radocha J, Robak P, Kim K, Cavo M, Suzuki K, Wilkes J, McNamara S, Phillips-Jones A, Morris K, Pompilus F, Purser M, Sule N, Kremer B, Loubert A, Bunod L, M'Hari M, Zhou XL, Fulci G, Mateos MV, Trudel S, DREAMM-8 investigators

doi: 10.1016/S2352-3026(25)00256-X

ASH 2025

Multiple Myeloma (MM)

LBA-1: Early MRD negativity following the novel in vivo CAR T-cell therapy KLN-1010 in patients with RRMM

EHA 2026

Multiple Myeloma (MM)

MajesTEC-3: Teclistamab plus daratumumab maintain improved PFS and MRD negativity across high-risk multiple myeloma populations

ASH 2025

Multiple Myeloma (MM)

BENEFIT: Isa-VRd achieves superior sustained MRD negativity in transplant-ineligible NDMM

EHA 2026

Multiple Myeloma (MM)

MonumenTAL-3: Talquetamab-daratumumab regimens significantly improve PFS in patients with RRMM

CHICAGO 2026

Multiple Myeloma (MM)

MajesTEC-9: Teclistamab significantly improves survival outcomes in patients with RRMM

WCLC 2025

Lung, Respiratory and Thoracic Cancer

EMPOWER-Lung 3: Cemiplimab plus chemotherapy provide sustained survival benefits in patients with advanced NSCLC

ESMO 2025

Breast Cancer

ASCENT-04/KEYNOTE-D19: Sacituzumab govitecan plus pembrolizumab maintains QoL and delays functional decline in patients with PD-L1-positive metastatic TNBC

Related content

DREAMM-7: Belantamab mafodotin combination achieves superior MRD outcomes in patients with RRMM

Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial

LBA-1: Early MRD negativity following the novel in vivo CAR T-cell therapy KLN-1010 in patients with RRMM

MajesTEC-3: Teclistamab plus daratumumab maintain improved PFS and MRD negativity across high-risk multiple myeloma populations

BENEFIT: Isa-VRd achieves superior sustained MRD negativity in transplant-ineligible NDMM

MonumenTAL-3: Talquetamab-daratumumab regimens significantly improve PFS in patients with RRMM

MajesTEC-9: Teclistamab significantly improves survival outcomes in patients with RRMM

EMPOWER-Lung 3: Cemiplimab plus chemotherapy provide sustained survival benefits in patients with advanced NSCLC

ASCENT-04/KEYNOTE-D19: Sacituzumab govitecan plus pembrolizumab maintains QoL and delays functional decline in patients with PD-L1-positive metastatic TNBC